Log In
BCIQ
Print this Print this
 

IPH4102

  Manage Alerts
Collapse Summary General Information
Company Innate Pharma S.A.
DescriptionHumanized mAb against killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2; CD158K)
Molecular Target Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 2 (KIR3DL2) (CD158K)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationCutaneous T cell lymphoma (CTCL)
Indication DetailsTreat cutaneous T cell lymphoma (CTCL); Treat relapsed or refractory cutaneous T cell lymphoma (CTCL); Treat Sezary syndrome (SS); Treat transformed mycosis fungoides (TMF)
Regulatory Designation EU - Orphan Drug (Treat cutaneous T cell lymphoma (CTCL))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today